Vanguard Group’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$563M Sell
12,193,986
-126,467
-1% -$5.66M 0.01% 988
2025
Q3
$444M Buy
12,320,453
+323,368
+3% +$10.7M 0.01% 1126
2025
Q2
$390M Sell
11,997,085
-46,720
-0.4% -$1.53M 0.01% 1166
2025
Q1
$455M Buy
12,043,805
+82,118
+0.7% +$6.57M 0.01% 1044
2024
Q4
$979M Buy
11,961,687
+521,204
+5% +$51.8M 0.02% 667
2024
Q3
$1.31B Buy
11,440,483
+1,643,488
+17% +$148M 0.02% 583
2024
Q2
$740M Buy
9,796,995
+59,741
+0.6% +$4.07M 0.01% 772
2024
Q1
$665M Buy
9,737,254
+1,284,883
+15% +$89M 0.01% 852
2023
Q4
$531M Buy
8,452,371
+168,125
+2% +$8.73M 0.01% 934
2023
Q3
$422M Buy
8,284,246
+47,872
+0.6% +$2.36M 0.01% 987
2023
Q2
$411M Buy
8,236,374
+1,704,058
+26% +$80.8M 0.01% 1041
2023
Q1
$245M Sell
6,532,316
-81,350
-1% -$3.45M 0.01% 1346
2022
Q4
$317M Buy
6,613,666
+2,161,521
+49% +$84.8M 0.01% 1137
2022
Q3
$107M Buy
4,452,145
+496,227
+13% +$12.6M ﹤0.01% 1747
2022
Q2
$86.1M Buy
3,955,918
+326,554
+9% +$7.56M ﹤0.01% 1912
2022
Q1
$87.6M Buy
3,629,364
+495,078
+16% +$10.8M ﹤0.01% 2016
2021
Q4
$74.6M Buy
3,134,286
+90,404
+3% +$2.1M ﹤0.01% 2131
2021
Q3
$77.2M Buy
3,043,882
+195,238
+7% +$4.73M ﹤0.01% 2130
2021
Q2
$64.1M Buy
2,848,644
+77,330
+3% +$1.58M ﹤0.01% 2238
2021
Q1
$54.7M Buy
2,771,314
+1,321,937
+91% +$33.3M ﹤0.01% 2264
2020
Q4
$38.5M Buy
1,449,377
+96,557
+7% +$3.59M ﹤0.01% 2334
2020
Q3
$66.8M Buy
1,352,820
+1,322,820
+4,409% +$52.7M ﹤0.01% 1871
2020
Q2
$948K Buy
+30,000
New +$965K ﹤0.01% 3626

Other funds holding PCVX